Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma

27 Jul 2021

Abstract excerpt

Telomerase reactivation during hepatocarcinogenesis is recurrently caused by two point mutations occurring most frequently at the nucleotide −124 (95%) and occasionally at the nucleotide −146 (<5%) upstream of the TERT translational start site in hepatocellular carcinoma (HCC). In this study, we designed a droplet digital PCR (ddPCR) assay to detect TERT promoter (TERTp) nucleotide change G>A at position −124 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Hepatitis B Virus Studies
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34359670
DOI: 10.3390/cancers13153771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular CarcinomaPMID 34359670Read ↗

Analysis of TERT promoter hotspot mutations using droplet digital PCR in hepatoblastoma and hepatocellular carcinoma.Semantic proximity Read ↗

TERT promoter mutation predicts the prognosis value of patients with HBV- related HCC who underwent hepatectomySemantic proximity Read ↗

Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.Semantic proximity Read ↗

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.Semantic proximity Read ↗

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.Semantic proximity Read ↗

Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinomaSemantic proximity Read ↗

Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.Semantic proximity Read ↗

Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.Semantic proximity Read ↗

TERT Promoter Mutations Combined with TP53 Mutations as Potential Biomarkers for Hepatocellular Carcinoma Recurrence and PrognosisSemantic proximity Read ↗

The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.Semantic proximity Read ↗

Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factorsSemantic proximity Read ↗

Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.